The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost‐Effectiveness
Open accessAbstract
BACKGROUND: The combination of tenofovir and emtricitabine shows promise as HIV preexposure prophylaxis (PrEP). We sought to forecast clinical, epidemiologic, and economic outcomes of PrEP, taking into account uncertainties regarding efficacy, the risks of developing drug resistance and toxicity, behavioral disinhibition, and drug costs. METHODS: We adapted a computer simulation of HIV acquisition, detection, and care to model PrEP among men who have sex with men and are at high risk of HIV infection (i.e., 1.6% mean annual incidence of HIV infection) in the United States. Base-case assumptions included 50% PrEP efficacy and monthly tenofovir-emtricitabine costs of $753. We used sensitivity analyses to examine the stability of results and to identify critical input parameters. RESULTS: In a cohort with a mean age of 34 years, PrEP reduced lifetime HIV infection risk from 44% to 25% and increased mean life expectancy from 39.9 to 40.7 years (21.7 to 22.2 discounted quality-adjusted life-years). Discounted mean lifetime treatment costs increased from $81,100 to $232,700 per person, indicating an incremental cost-effectiveness ratio of $298,000 per quality-adjusted life-year gained. Markedly larger reductions in lifetime infection risk (from 44% to 6%) were observed with the assumption of greater (90%) PrEP efficacy. More-favorable incremental cost-effectiveness ratios were obtained by targeting younger populations with a higher incidence of infection and by improvements in the efficacy and cost of PrEP. CONCLUSIONS: PrEP could substantially reduce the incidence of HIV transmission in populations at high risk of HIV infection in the United States. Although it is unlikely to confer sufficient benefits to justify the current costs of tenofovir-emtricitabine, price reductions and/or increases in efficacy could make PrEP a cost-effective option in younger populations or populations at higher risk of infection. Given recent disappointments in HIV infection prevention and vaccine development, additional study of PrEP-based HIV prevention is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020298 · Cited by 2,451
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.
Bailey, R. C., Moses, S., Parker, C. B., Agot, K., Maclean, I., Krieger, J. N., Williams, C. F., Campbell, R. T., & Ndinya-Achola, J. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60312-2 · Cited by 2,292
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.
Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., Kiwanuka, N., Moulton, L. H., Chaudhary, M. A., Chen, M. Z., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60313-4 · Cited by 2,226
Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness
Tengs, T. O., Adams, M. E., Pliskin, J. S., Safran, D. G., Siegel, J. E., Weinstein, M. C., & Graham, J. D. (1995) · Risk Analysis · doi:10.1111/j.1539-6924.1995.tb00330.x · Cited by 1,321
The rgp120 HIV Vaccine Study Group (2005) · The Journal of Infectious Diseases · doi:10.1086/428404 · Cited by 952
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051871 · Cited by 880
Willingness to Pay for a Quality-adjusted Life Year: In Search of a Standard
Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., & Weissert, W. G. (2000) · Medical Decision Making · doi:10.1177/0272989x0002000310 · Cited by 850
What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation?
Ubel, P. A., Hirth, R. A., Chernew, M. E., & Fendrick, A. M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1637 · Cited by 588
The Survival Benefits of AIDS Treatment in the United States
Walensky, R. P., Paltiel, A. D., Losina, E., Mercincavage, L. M., Schackman, B. R., Sax, P. E., Weinstein, M. C., & Freedberg, K. A. (2006) · The Journal of Infectious Diseases · doi:10.1086/505147 · Cited by 581
Self-citationGrinsztejn, B., Nguyen, B.-Y., Katlama, C., Gatell, J. M., Lazzarin, A., Vittecoq, D., Gonzalez, C. J., Chen, J., Harvey, C. M., & Isaacs, R. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60597-2 · Cited by 574
Highly Active Antiretroviral Therapy and Sexual Risk Behavior: A Meta-analytic Review
Crepaz, N., Hart, T. A., & Marks, G. (2004) · JAMA · doi:10.1001/jama.292.2.224 · Cited by 565
Expanded Screening for HIV in the United States — An Analysis of Cost-Effectiveness
Paltiel, A. D., Weinstein, M. C., Kimmel, A. D., Seage, G. R., Losina, E., Zhang, H., Freedberg, K. A., & Walensky, R. P. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa042088 · Cited by 553
Self-citationThe Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg, K. A., Losina, E., Weinstein, M. C., Paltiel, A. D., Cohen, C. J., Seage, G. R., Craven, D. E., Zhang, H., Kimmel, A. D., & Goldie, S. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441108 · Cited by 508
Self-citationThe Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States
Schackman, B. R., Gebo, K. A., Walensky, R. P., Losina, E., Muccio, T., Sax, P. E., Weinstein, M. C., Seage, G. R., Moore, R. D., & Freedberg, K. A. (2006) · Medical Care · doi:10.1097/01.mlr.0000228021.89490.2a · Cited by 410
Self-citationGarcía-Lerma, J. G., Otten, R. A., Qari, S. H., Jackson, E., Cong, M.-E., Masciotra, S., Luo, W., Kim, C., Adams, D. R., Monsour, M., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050028 · Cited by 350
Padian, N. S., van der Straten, A., Ramjee, G., Chipato, T., de Bruyn, G., Blanchard, K., Shiboski, S., Montgomery, E. T., Fancher, H., Cheng, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60950-7 · Cited by 337
Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice
Denton, P. W., Estes, J. D., Sun, Z., Othieno, F. A., Wei, B. L., Wege, A. K., Powell, D. A., Payne, D., Haase, A. T., & Garcia, J. V. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050016 · Cited by 319
Koblin, B. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16588-4 · Cited by 308
Peterson, L., Taylor, D., Roddy, R., Belai, G., Phillips, P., Nanda, K., Grant, R., Clarke, E. E. K., Doh, A. S., Ridzon, R., et al. (2007) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0020027 · Cited by 277
Johnson, M., Grinsztejn, B., Rodriguez, C., Coco, J., DeJesus, E., Lazzarin, A., Lichtenstein, K., Rightmire, A., Sankoh, S., & Wilber, R. (2005) · AIDS · doi:10.1097/01.aids.0000166091.39317.99 · Cited by 248
Millett, G. A. (2008) · JAMA · doi:10.1001/jama.300.14.1674 · Cited by 220
Paltiel, A. D., Walensky, R. P., Schackman, B. R., Seage, G. R., Mercincavage, L. M., Weinstein, M. C., & Freedberg, K. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-11-200612050-00004 · Cited by 196
Self-citationPrivate choices and public health: the AIDS epidemic in an economic perspective
(1994) · Choice Reviews Online · doi:10.5860/choice.31-5486 · Cited by 192
Desai, K., Sansom, S. L., Ackers, M. L., Stewart, S. R., Hall, H. I., Hu, D. J., Sanders, R., Scotton, C. R., Soorapanth, S., Boily, M.-C., et al. (2008) · AIDS · doi:10.1097/qad.0b013e32830e00f5 · Cited by 163
Coca, S. G., & Perazella, M. A. (2002) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200212000-00011 · Cited by 154
Nelson, M. R., Arastéh, K., Clotet, B., Cooper, D. A., Henry, K., Katlama, C., Lalezari, J. P., Lazzarin, A., Montaner, J. S. G., O’Hearn, M., et al. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000185314.56556.c3 · Cited by 152
Johnson, M. A., Gathe, J., Podzamczer, D., Molina, J., Naylor, C., Chiu, Y., King, M. S., Podsadecki, T. J., Hanna, G. J., & Brun, S. C. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000242449.67155.1a · Cited by 116
Are US Populations Appropriate for Trials of Human Immunodeficiency Virus Vaccine?
Seage, G. R., Holte, S., Metzger, D. S., Koblin, B. A., Gross, M., Celum, C., Marmor, M. F., WOODY, G. E., Mayer, K. H., Stevens, C. E., et al. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.7.619 · Cited by 110
Pre-exposure prophylaxis for HIV infection: what if it works?
Paxton, L. A., Hope, T., & Jaffe, H. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61053-8 · Cited by 94
Hightow‐Weidman, L., Leone, P. A., MacDonald, P. D. M., McCoy, S. I., Sampson, L. A., & Kaplan, A. H. (2006) · Sexually Transmitted Diseases · doi:10.1097/01.olq.0000216031.93089.68 · Cited by 89
Promote HIV Chemoprophylaxis Research, Don't Prevent It
Grant, R. M., Buchbinder, S., Cates, W., Clarke, E. E. K., Coates, T. J., Cohen, M. S., Delaney, M., Flores, G., Goicochea, P., Gonsalves, G., et al. (2005) · Science · doi:10.1126/science.1116204 · Cited by 76
Mayer, K. H., Mimiaga, M. J., Cohen, D., Grasso, C., Bill, R., VanDerwarker, R., & Fisher, A. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318162afcb · Cited by 68
Pre-Exposure Chemoprophylaxis (PREP) as an HIV Prevention Strategy
Youle, M. S., & Wainberg, M. A. (2003) · Journal of the International Association of Physicians in AIDS Care · doi:10.1177/154510970300200302 · Cited by 50
Smith, D. M., Drumright, L. N., Frost, S. D. W., Cheng, W. S., Espitia, S. A., Daar, E. S., Little, S. J., & Gorbach, P. M. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000243100.49899.2a · Cited by 24
Antiretroviral Therapy for Prevention of HIV Infection: New Clues From an Animal Model
Cohen, M. S., & Kashuba, A. D. M. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050030 · Cited by 23
Cited by
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
Broder, S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.002 · Cited by 520
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
Cihlar, T., & Ray, A. S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.014 · Cited by 375
Smith, D. K., Pals, S. L., Herbst, J. H., Shinde, S., & Carey, J. W. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318256b2f6 · Cited by 278
Current status and challenges of antiretroviral research and therapy
Esté, J. A., & Cihlar, T. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.007 · Cited by 277
Metadata
- Authors
- Paltiel, A. D., Freedberg, K. A., Scott, C. A., Schackman, B. R., Losina, E., Wang, B., Seage III, G. R., Sloan, C. E., Sax, P. E., & Walensky, R. P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-15
- Volume
- 48
- Issue
- 6
- Pages
- 806-815
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2047690132
- Cited by
- 259
- References
- 36
- FWCI
- 19.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.